Sponsors (14)
Authorizes NIH/HHS to expand and coordinate research, public education, and provider information on triple‑negative breast cancer and authorizes funding for FY2026–FY2031.
Official title: To provide for research and education with respect to triple-negative breast cancer, and for other purposes.
Introduced March 3, 2025 by Joseph Morelle · Last progress March 3, 2025
The bill boosts education, outreach, and coordinated research to reduce triple-negative breast cancer disparities and improve outcomes—especially for minority women—but requires sustained federal funding, administrative capacity, and culturally careful implementation to avoid costs, service strain, and potential stigma.
Women—especially African-American and Hispanic women—gain substantially better access to information about triple-negative breast cancer through CDC public education and targeted outreach, improving awareness of incidence, risks, and treatment options.
Patients (women at risk for TNBC) could see earlier detection and therefore better survival outcomes if education and outreach drive screening and prompt care (localized breast cancer survival much higher than late-stage).
Researchers and the research ecosystem receive stronger, coordinated NIH and ORWH support and increased funding authority for expanded TNBC studies, improving data, understanding of disparities, and prospects for better treatments.
Taxpayers and federal budgets could face higher, open-ended costs because the bill authorizes unspecified (“such sums as may be necessary”) funding for multiple years and could expand screening, outreach, and research programs.
Hospitals and oncology services—particularly in underserved areas—may experience increased demand for screening, diagnosis, and treatment, straining capacity and access to care if resources and workforce are not expanded.
CDC and HRSA may incur additional administrative and programmatic burdens to run outreach, education, and coordination activities, potentially diverting staff and funds from other priorities absent new appropriations.
Based on analysis of 3 sections of legislative text.
Directs the Department of Health and Human Services and the National Institutes of Health to expand, coordinate, and fund research, public education, and health‑care provider information on triple‑negative breast cancer (TNBC). It authorizes unspecified appropriations for FY2026–FY2031 for NIH research and for HHS agencies (CDC and HRSA) to develop and disseminate information about TNBC incidence, elevated risks for minority women, and treatment options. Requires the NIH Director to coordinate TNBC research across relevant NIH institutes with the Office of Research on Women's Health leading coordination; directs CDC to run public awareness campaigns and allows partnerships with nonprofits and media; directs HRSA to provide TNBC information to clinicians and health care providers. Defines “minority women” by cross‑reference to an existing statute.